Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FABLOx in Metastatic Pancreatic Adenocarcinoma
NCT02620800Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jan 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Celgene Corporation. Primary endpoints: Dose Limiting Toxicities, 1 Year Survival Rate and 1 more. Started Jan 2016; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02620800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620800.